IL37 and systemic lupus erythematosus: In addition, in terms of clinical drugs, IL-23 can potentially be targeted to treat the symptoms of AD like SLE, psoriasis, IBD, and RA (Floss et al., 2015), preventing IL-23 from binding to its receptor has become a mechanism of current therapy, and IL-23 inhibitors have been shown to be effective (Han et al., 2020).